Published in
American Association for the Advancement of Science, Science Signaling, 551(11), 2018
DOI: 10.1126/scisignal.aat9773
Links
Tools
Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)
Journal article published in 2018 by
Emiliano Cocco,
F. Javier Carmona,
Pedram Razavi,
Helen H. Won,
Yanyan Cai 
,
Valentina Rossi ,
Carmen Chan ,
James Cownie,
Joanne Soong ,
Eneda Toska ,
Sophie G. Shifman ,
Ivana Sarotto ,
Peter Savas ,
Michael J. Wick ,
Kyriakos P. Papadopoulos
and other authors.
,
Valentina Rossi ,
Carmen Chan ,
James Cownie,
Joanne Soong ,
Eneda Toska ,
Sophie G. Shifman ,
Ivana Sarotto ,
Peter Savas ,
Michael J. Wick ,
Kyriakos P. Papadopoulos
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Metastatic breast cancer patients with coexistent HER2 mutation and amplification respond to neratinib.